We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
XENE's Depression Trial Setback: Is Its Pipeline Still Attractive?
Read MoreHide Full Article
Key Takeaways
Xenon paused enrollment in phase III depression trials after unexpected side effects emerged.
Xenon is reviewing dose adjustments, with top-line X-NOVA2 results expected in the first quarter of 2027.
Azetukalner's FDA application for FOS and ongoing epilepsy trials offer potential growth opportunities.
Xenon Pharmaceuticals (XENE - Free Report) is facing investor concerns after a safety-related setback in its late-stage depression program. The company is evaluating its lead pipeline asset, azetukalner, in phase III X-NOVA2 and X-NOVA3 studies for the treatment of patients with major depressive disorder (MDD) and in the X-CEED study for bipolar depression (BPD) I or II.
Azetukalner is an experimental oral drug designed to open Kv7 potassium channels, which help regulate electrical activity in the brain. Xenon is studying the drug for both depression and epilepsy.
In September 2026, Xenon voluntarily paused enrollment of new patients temporarily in its ongoing phase III depression studies after unexpected neurological and psychiatric side effects were observed. The side effects included confusion, speech difficulties and problems with muscle coordination, along with a small number of cases classified as psychosis. These events had not been observed in the earlier phase II depression study. However, the setback does not mean the drug failed to demonstrate efficacy in these trials. The company took this precaution after reviewing the safety data and consulting its independent safety monitoring board.
Xenon is reviewing potential dose adjustments, while patients already enrolled in the studies remain active. The development raises questions about the drug's safety and commercial potential, but the company's epilepsy program still offers growth opportunities.
Meanwhile, Xenon plans to complete the six-week treatment period for patients already enrolled in the X-NOVA2 study and release topline results in the first quarter of 2027.
Year to date, XENE's shares have lost 23.1% against the industry’s 2.9% growth.
Image Source: Zacks Investment Research
Epilepsy Pipeline Remains the Key Growth Driver for XENE
Xenon's prospects are not limited to psychiatric disorders. The company has submitted a new drug application to the FDA for azetukalner to treat focal onset seizures (FOS), a common form of epilepsy. The application is supported by positive clinical results, including statistically significant reductions in monthly seizure frequency compared with placebo in the phase IIb X-TOLE and phase III X-TOLE2 studies. If approved, azetukalner could become Xenon's first commercial product.
Xenon is also evaluating azetukalner in the phase III X-TOLE3 study for focal onset seizures and the X-ACKT study for primary generalized tonic-clonic seizures. These programs could expand the drug's potential market if they produce favorable results.
Other Pipeline Candidates Offer Longer-Term Potential
Beyond azetukalner, Xenon is developing early-stage candidates targeting ion channels involved in pain. These include XEN1701 and XEN1720, which target the Nav1.7 sodium channel, and XEN1120, a Kv7 potassium channel opener. The company is investigating these candidates for pain-related conditions, although they remain in early clinical development and are much less advanced than azetukalner. Positive results could eventually diversify Xenon's pipeline.
Xenon faces competition from established drugmakers in both depression and epilepsy. Vanda Pharmaceuticals (VNDA - Free Report) is evaluating Bysanti (milsaperidone) as a once-daily adjunctive treatment for MDD in an ongoing phase III study, with top-line data expected in the first half of 2027. Earlier this year, Vanda’s Bysanti received FDA approval for bipolar I disorder and schizophrenia in adults. Johnson & Johnson (JNJ - Free Report) is another key competitor to Xenon in the depression market. Its drug Spravato (esketamine) is FDA-approved for adults with treatment-resistant depression. Hence, Johnson & Johnson could pose a tough competition to Xenon if azetukalner receives approval for depression.
View the Zacks #1 Rank List
Image: Bigstock
XENE's Depression Trial Setback: Is Its Pipeline Still Attractive?
Key Takeaways
Xenon Pharmaceuticals (XENE - Free Report) is facing investor concerns after a safety-related setback in its late-stage depression program. The company is evaluating its lead pipeline asset, azetukalner, in phase III X-NOVA2 and X-NOVA3 studies for the treatment of patients with major depressive disorder (MDD) and in the X-CEED study for bipolar depression (BPD) I or II.
Azetukalner is an experimental oral drug designed to open Kv7 potassium channels, which help regulate electrical activity in the brain. Xenon is studying the drug for both depression and epilepsy.
In September 2026, Xenon voluntarily paused enrollment of new patients temporarily in its ongoing phase III depression studies after unexpected neurological and psychiatric side effects were observed. The side effects included confusion, speech difficulties and problems with muscle coordination, along with a small number of cases classified as psychosis. These events had not been observed in the earlier phase II depression study. However, the setback does not mean the drug failed to demonstrate efficacy in these trials. The company took this precaution after reviewing the safety data and consulting its independent safety monitoring board.
Xenon is reviewing potential dose adjustments, while patients already enrolled in the studies remain active. The development raises questions about the drug's safety and commercial potential, but the company's epilepsy program still offers growth opportunities.
Meanwhile, Xenon plans to complete the six-week treatment period for patients already enrolled in the X-NOVA2 study and release topline results in the first quarter of 2027.
Year to date, XENE's shares have lost 23.1% against the industry’s 2.9% growth.
Image Source: Zacks Investment Research
Epilepsy Pipeline Remains the Key Growth Driver for XENE
Xenon's prospects are not limited to psychiatric disorders. The company has submitted a new drug application to the FDA for azetukalner to treat focal onset seizures (FOS), a common form of epilepsy. The application is supported by positive clinical results, including statistically significant reductions in monthly seizure frequency compared with placebo in the phase IIb X-TOLE and phase III X-TOLE2 studies. If approved, azetukalner could become Xenon's first commercial product.
Xenon is also evaluating azetukalner in the phase III X-TOLE3 study for focal onset seizures and the X-ACKT study for primary generalized tonic-clonic seizures. These programs could expand the drug's potential market if they produce favorable results.
Other Pipeline Candidates Offer Longer-Term Potential
Beyond azetukalner, Xenon is developing early-stage candidates targeting ion channels involved in pain. These include XEN1701 and XEN1720, which target the Nav1.7 sodium channel, and XEN1120, a Kv7 potassium channel opener. The company is investigating these candidates for pain-related conditions, although they remain in early clinical development and are much less advanced than azetukalner. Positive results could eventually diversify Xenon's pipeline.
Xenon Pharmaceuticals Inc. Price and Consensus
Xenon Pharmaceuticals Inc. price-consensus-chart | Xenon Pharmaceuticals Inc. Quote
XENE’s Competitive Landscape in Depression Market
Xenon faces competition from established drugmakers in both depression and epilepsy. Vanda Pharmaceuticals (VNDA - Free Report) is evaluating Bysanti (milsaperidone) as a once-daily adjunctive treatment for MDD in an ongoing phase III study, with top-line data expected in the first half of 2027. Earlier this year, Vanda’s Bysanti received FDA approval for bipolar I disorder and schizophrenia in adults. Johnson & Johnson (JNJ - Free Report) is another key competitor to Xenon in the depression market. Its drug Spravato (esketamine) is FDA-approved for adults with treatment-resistant depression. Hence, Johnson & Johnson could pose a tough competition to Xenon if azetukalner receives approval for depression.
XENE's Zacks Rank
Xenon stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 (Strong Buy) Rank stocks here.